24 September 2021 - - US-based biotechnology company Moderna, Inc. (NASDAQ: MRNA) has inked a supply agreement with the government of Peru for 20 m doses of Moderna's COVID-19 vaccine to begin delivery in the first quarter of 2022, the company said.

The COVID-19 Vaccine Moderna is not currently approved for use in Peru, and the company will work with regulators to pursue necessary approvals prior to distribution.

Moderna's mRNA platform builds on advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases.

COVID-19 Vaccine Moderna is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein. On December 18, 2020, the US FDA authorized the emergency use of the Moderna COVID-19 Vaccine in individuals 18 years of age or older.

Moderna has received emergency (or other conditional, interim or provisional) authorization for use of its COVID-19 vaccine in adults from health agencies in more than 50 countries and an Emergency Use Listing from the World Health Organization.